Welcome to our dedicated page for Inspire Medical SEC filings (Ticker: INSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on minimally invasive neurostimulation therapy for moderate to severe obstructive sleep apnea. These documents offer detailed insight into how Inspire reports its financial results, risks, and corporate developments.
Annual reports on Form 10-K and quarterly reports on Form 10-Q contain management’s discussion and analysis of financial condition and results of operations, along with risk factor disclosures. In these filings, Inspire describes its dependence on Inspire therapy for revenues, coverage and reimbursement considerations, competition from other therapies and technologies, reliance on third-party suppliers and contract manufacturers, international operations, information technology and cybersecurity risks, and other factors that may affect future performance.
Current reports on Form 8-K document specific material events. Recent 8-K filings have covered quarterly and annual financial results, preliminary and unaudited revenue ranges, expectations regarding the release of valuation allowances on U.S. deferred tax assets, authorization of share repurchase programs, and leadership changes such as the transition and appointment of the Chief Financial Officer. These filings often incorporate press releases and investor presentation materials by reference.
Investors can also review compensatory arrangements and executive employment agreements described in 8-K items, which outline base salary, bonus targets, equity awards, severance terms, and change-of-control provisions for senior executives. Such disclosures provide transparency into Inspire’s governance and incentive structures.
On Stock Titan, Inspire’s SEC filings are updated as they are made available on EDGAR. AI-powered summaries highlight key points from lengthy documents, helping readers quickly identify themes such as revenue drivers tied to Inspire therapy, guidance ranges, risk factors, and notable corporate actions, without replacing the need to consult the full official filings.
Inspire Medical Systems describes its business built around Inspire, a fully implantable, closed-loop neurostimulation system for moderate to severe obstructive sleep apnea (OSA). The device gently stimulates the hypoglossal nerve during sleep to keep the airway open and is implanted in a 30‑ to 90‑minute outpatient procedure, with a battery designed to last about 11 years.
The company highlights extensive clinical evidence, including its pivotal STAR trial showing about a 70% median reduction in apnea‑hypopnea index from 29.3 to 9.0 events per hour at 12 months and sustained benefit to five years, and real‑world ADHERE registry data where patients used therapy 5.7 hours per night with 90% satisfaction and 92% willing to choose the procedure again. More than 125,000 patients have been treated across the U.S., Europe, and Asia.
Inspire sells primarily to hospitals and ambulatory surgery centers through a direct sales force, with 295 U.S. sales territories and 21 outside the U.S. It emphasizes broad insurance coverage, including positive policies from all large national commercial payors covering over 300 million U.S. lives, Medicare coverage through all seven MACs, and contracts with the Veterans Health Administration.
Inspire Medical Systems officer Carlton Weatherby, Chief Strategy and Growth Officer, reported a tax-withholding disposition of 327 shares of common stock on February 9, 2026 at $66.33 per share. After this transaction, Weatherby directly owned 7,130 shares of Inspire Medical Systems common stock.
Phillips Bryan K reported disposition transactions in a Form 4 filing for INSP. The filing lists transactions totaling 327 shares at a weighted average price of $66.33 per share. Following the reported transactions, holdings were 13,070 shares.
Herbert Timothy P. reported disposition transactions in a Form 4 filing for INSP. The filing lists transactions totaling 968 shares at a weighted average price of $66.33 per share. Following the reported transactions, holdings were 34,321 shares.
Inspire Medical Systems, Inc. executive John Rondoni, the Chief Product and Innovation Officer, reported a tax-related share disposition. On February 9, 2026, 327 shares of common stock were withheld by the company at $66.33 per share to cover taxes on a vested restricted stock unit award. After this withholding, Rondoni directly beneficially owned 13,470 common shares.
Buchholz Richard reported disposition transactions in a Form 4 filing for INSP. The filing lists transactions totaling 327 shares at a weighted average price of $66.33 per share. Following the reported transactions, holdings were 44,567 shares.
Inspire Medical Systems' interim CFO Richard Buchholz filed an initial Form 3 reporting his beneficial ownership in Inspire Medical Systems, Inc. He directly holds 44,567 common shares, including 5,974 restricted stock units, and has employee stock options over 4,376, 5,450, 5,924 and 17,300 shares. He also reports indirect ownership of 1,475 common shares held by his son.
Inspire Medical Systems reported solid growth for 2025 while signaling a slower 2026 and governance changes. Revenue rose 14% to
Fourth quarter 2025 revenue grew 12% to
The filing also outlines a proposal to declassify the board, moving to annual director elections after a phase-in, and bylaw amendments to remove the “for cause only” director removal provision, subject to shareholder approval at the 2026 annual meeting.
Inspire Medical Systems, Inc. received a Schedule 13G from several Wellington entities reporting a significant institutional ownership position in its common stock as of 12/31/2025.
The Wellington group entities report beneficial ownership of 2,211,091 shares of Inspire Medical common stock, representing 7.61% of the outstanding class. They report no sole voting or dispositive power, but shared voting power over 1,934,784 shares and shared dispositive power over 2,211,091 shares.
The securities are owned of record by clients of various Wellington investment advisers, which are controlled through a chain of holding companies headed by Wellington Management Group LLP. Wellington certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Inspire Medical.
Inspire Medical Systems, Inc. director Gary Lee Ellis reported receiving 304 shares of common stock on 01/15/2026 at a price of $96.47 per share. These shares were issued in lieu of cash fees under the company’s Non-Employee Director Compensation Policy, meaning his board compensation was taken in stock rather than cash.
After this award, Ellis beneficially owns 6,758 shares of Inspire Medical Systems common stock in direct ownership. The filing reflects routine director compensation rather than an open-market trade.
FAQ
What is the current stock price of Inspire Medical (INSP)?
What is the market cap of Inspire Medical (INSP)?
